VXRT (Vaxart) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VXRT Vaxart Inc VXRT
49 GF Score
Price $0.49
! 3 Warning Signs
View Full Analysis

What is Vaxart Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

VXRT
49GF Score
Vaxart Inc VXRT
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxart Business Description

Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc. is a clinical-stage biotechnology company based in the United States that develops oral recombinant vaccines delivered in tablet form rather than by injection. Its vaccines are built on a proprietary vector-adjuvant-antigen platform that uses a modified adenovirus vector to elicit immune responses in the gastrointestinal tract and systemically. The company's development pipeline targets infectious diseases including norovirus, seasonal influenza, respiratory syncytial virus (RSV), human papillomavirus (HPV), and coronaviruses, with norovirus and coronavirus programs among its most advanced. Vaxart also develops a proprietary oral vaccine adjuvant and has explored tablet vaccine formulations intended to be room-temperature stable and self-administered. The company operates in a single reporting segment, the discovery and development of oral recombinant vaccines, and conducts its activities primarily in the United States. As a clinical-stage business, it has no approved products and generates no product revenue, funding operations through equity offerings, grants, and collaboration agreements.
49GF Score

Get the complete analysis for VXRT

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.49
Price